Clopidogrel hyper-response and bleeding risk in neurointerventional procedures

American Journal of Neuroradiology

Volumn 34, Issue 4, 2013, Pages 721-726

  Goh, C ^a   Churilov, L ^b,c   Mitchell, P ^a   Dowling, R ^a   Yan, B ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEPARIN; PURINERGIC P2Y12 RECEPTOR;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; MALE; NEUROINTERVENTIONAL PROCEDURE; NEUROLOGICAL AND SENSORIAL PROCEDURES; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; ANTICOAGULANTS; BLOOD PLATELETS; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOVASCULAR PROCEDURES; FEMALE; HEPARIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE;

EID: 84876727678     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3418     Document Type: Article

References (27)

1. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 2001;13:767-71 (Pubitemid 33759191)
2. Cohen M. Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009;74:579-97
3. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 2007;154:221-31 (Pubitemid 47069129)
4. Musallam KM, Charafeddine K, Bitar A, et al. Resistance to aspirin and clopidogrel therapy. Int J Lab Hematol 2011:33:1-18
5. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clin Pharmacol Ther 2011;90:328-32
6. Ari H, Ozkan H, Karacinar A, et al. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2012;157:374-80
7. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention. J AmColl Cardiol 2010;56: 1447-55
8. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000 (Pubitemid 351844676)
9. Aradi D, Komó csi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010;160:543-51
10. Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: Approaches to the FDA "boxed warning"-a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537-57
11. Sibbing D, Schultz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-56
12. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome: Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325-29
13. Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: Assessment by different bleeding classifications. Eur Heart J 2010;31:227-35
14. van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets 2008;19:479-88
15. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009;157:562.e1-e9
16. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: Head-tohead comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010;103:39-45
17. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62
18. Ryu DS, Hong C-K, Sim YS, et al. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319-24
19. Muller-Schunk S, Linn J, Peters N, et al. Monitoring of clopidogrelrelated platelet inhibition: Correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29: 786-91 (Pubitemid 351571565)
20. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-85 (Pubitemid 351287881)
21. Lee DH, Arat A, Morsi H, et al. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: A single-center experience. AJNR Am J Neuroradiol 2008;29:1389-94
22. Byrne JV, Beltechi R, Yarnold JA, et al. Early experience in the treatment of intra-cranial aneurysms by endovascular flow diversion: A multicentre prospective study. PLoS One 2010;5. pii: E12492
23. Nelson PK, Lylyk P, Szikora I, et al. The Pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011;32:34-40
24. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ 2011:343: D4588
25. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-12
26. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-18
27. Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010;8: 1685-93